Apraclonidine Shortage: What Providers and Prescribers Need to Know in 2026

If your patients are reporting difficulty filling Apraclonidine prescriptions, they're not wrong. While Apraclonidine (brand name Iopidine) is not listed on the FDA's official Drug Shortage Database as of early 2026, a persistent practical availability gap continues to affect patients at the retail pharmacy level.

This briefing covers the current supply landscape, prescribing implications, cost and access considerations, and tools that can help your practice and your patients navigate these challenges.

Current Supply Status and Timeline

Apraclonidine has not been subject to a formal FDA-reported shortage. However, the medication's limited prescribing volume creates a recurring pattern:

• Retail pharmacies rarely stock Apraclonidine 0.5% due to low turnover and shelf-life considerations
• Apraclonidine 1% is primarily distributed through specialty and clinic-based pharmacies for perioperative use
• Generic Apraclonidine is manufactured by a small number of companies, and minor supply disruptions can create regional gaps
• No new ANDA approvals or additional manufacturers have entered the market recently

The net result: supply exists within the distribution chain, but patients frequently encounter "not in stock" messages when attempting to fill at their usual pharmacy.

Prescribing Implications

The limited retail availability of Apraclonidine has several clinical implications for ophthalmologists, optometrists, and neuro-ophthalmologists:

Short-Term Adjunctive Glaucoma Therapy (0.5%)

Apraclonidine 0.5% is FDA-approved for short-term adjunctive use in patients on maximally tolerated medical therapy. Key considerations:

• Tachyphylaxis: Efficacy tends to diminish over weeks to months in a significant portion of patients
• Allergic reaction rate: Up to 48% of patients develop allergic-type follicular conjunctivitis with continued use, limiting long-term utility
• Practical limitation: Given the above, many providers already favor Brimonidine (Alphagan P) for sustained alpha-2 agonist therapy

Perioperative IOP Control (1%)

For prevention of post-laser IOP spikes (argon laser trabeculoplasty, argon laser iridotomy, Nd:YAG posterior capsulotomy), the 1% formulation remains the FDA-approved choice. If your clinic relies on Apraclonidine 1%:

• Maintain a dedicated clinic supply rather than relying on retail pharmacy dispensing
• Work with your specialty distributor to ensure consistent stock
• Brimonidine 0.2% is a well-studied off-label alternative for perioperative IOP control if Apraclonidine 1% is unavailable

Horner Syndrome Diagnosis

Apraclonidine 0.5% is widely used as a pharmacologic test for Horner syndrome (reversal of anisocoria due to denervation supersensitivity). If your practice uses this test regularly:

• Keep a small supply on hand specifically for diagnostic purposes
• Note that the 0.5% concentration is the standard for this use — the 1% formulation has higher rates of false positives

Availability Picture: Where Supply Exists

Generic Apraclonidine 0.5% is available through:

• Major wholesalers (McKesson, AmerisourceBergen, Cardinal Health) — retail pharmacies can special-order, typically 1-2 business day turnaround
• Online pharmacies — Cost Plus Drugs carries generic Apraclonidine HCl 0.5% at transparent pricing
• Independent pharmacies — often more willing to stock or quickly order niche ophthalmic medications

Brand Iopidine (Alcon) distribution is more limited and typically available through specialty distributors.

Cost and Access Considerations

Cost can be a barrier, particularly for uninsured or underinsured patients:

• Retail cash price: $86–$128 for 5 mL of generic 0.5% solution
• With discount coupons (GoodRx, SingleCare): $13–$73
• Insurance coverage: Generic Apraclonidine is covered by most commercial plans and Medicare Part D (typically Tier 2 or 3)
• Prior authorization: Some plans require PA or step therapy through Brimonidine first
• Patient assistance: The Alcon Cares Patient Assistance Program may cover brand Iopidine for qualifying patients; NeedyMeds and RxAssist can help identify additional resources

For a patient-facing cost guide you can share, see How to Save Money on Apraclonidine.

Tools and Resources for Your Practice

Medfinder for Providers offers real-time pharmacy stock checking that you and your staff can use to identify pharmacies with Apraclonidine in stock before sending a prescription. This can dramatically reduce patient callbacks and abandoned prescriptions.

Recommended workflow:

1. Before e-prescribing Apraclonidine, check medfinder.com/providers for nearby pharmacies with current stock
2. Send the prescription to a pharmacy confirmed to have it available
3. If unavailable locally, consider directing the patient to an online pharmacy like Cost Plus Drugs
4. Document alternative options discussed in case the patient needs to switch

For a detailed guide on helping patients navigate access, see our companion article: How to Help Your Patients Find Apraclonidine in Stock.

Alternative Medications: Quick Reference

When Apraclonidine is unavailable or a patient develops tolerance or allergy:

• Brimonidine 0.2% (Alphagan P): More selective alpha-2 agonist, lower allergy rate, preferred for chronic therapy. Also effective perioperatively.
• Timolol 0.5% (Timoptic): Beta-blocker, widely available, very affordable ($5–$15). Avoid in asthma/COPD/bradycardia.
• Dorzolamide 2% (Trusopt): Topical CAI, can be combined with Timolol (Cosopt). Good adjunctive option.
• Latanoprost 0.005% (Xalatan): Prostaglandin analog, first-line for chronic open-angle glaucoma. Once-daily dosing.

For a patient-facing alternatives guide to share, see Alternatives to Apraclonidine.

Looking Ahead

The Apraclonidine availability challenge is unlikely to resolve on its own. As a low-volume specialty product, it will likely remain inconsistently stocked at retail pharmacies. Proactive prescribing workflows — checking stock before prescribing, maintaining clinic supplies for perioperative use, and having alternatives ready — remain the most effective strategies.

The evolving MIGS landscape may also reduce some patients' dependence on topical medications over time, though Apraclonidine's perioperative and diagnostic roles will remain relevant.

Final Thoughts

Apraclonidine remains a valuable tool in the ophthalmology armamentarium, but its niche status means providers need to be proactive about access. Checking stock before prescribing, keeping clinic supplies for surgical and diagnostic use, and having ready alternatives ensures your patients don't face treatment gaps.

Visit Medfinder for Providers to streamline medication availability checks for your practice. For additional clinical context, see our guides on Apraclonidine drug interactions and helping patients save money on Apraclonidine.